Holen Sie sich die Stockscreener-App
10.47
5.62%
0.6928
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Special Edition: Why Can’t We Cure Cancer? A National Conversation | Full CUOMO Show 2/27 - ImmunityBio
ImmunityBio Stock Pre-Market (+6.5%): Phase 2 Trial Enrollment Completed Early - Trefis
ImmunityBio (NASDAQ:IBRX) Shares Up 2.4%Still a Buy? - MarketBeat
Key facts: ImmunityBio completes Phase 2 trial enrollment; conference call set - TradingView
Promising Biotech Stocks To ConsiderFebruary 27th - MarketBeat
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 - BioSpace
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds - Stocktwits
ImmunityBio Trial Progress Puts Anktiva’s Global Cancer Potential in Focus - Yahoo Finance
IBRX Stock Price, Forecast & Analysis | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio (NASDAQ:IBRX) Director Sells $900,750.00 in Stock - MarketBeat
Simon, director, sells ImmunityBio (IBRX) shares worth $900k - Investing.com
Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum - Yahoo Finance
ImmunityBio Grapples with Allegations as Stock Tumbles - timothysykes.com
ImmunityBio (IBRX) loses 17% to profit-taking after intra-day high - MSN
ImmunityBio Investors Rally Behind Cancer Trial Milestone - Benzinga
IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up - Stocktwits
ImmunityBio completes enrollment in bladder cancer trial - Investing.com
ImmunityBio completes enrollment in bladder cancer trial By Investing.com - Investing.com UK
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High - Finviz
Patrick Soon-Shiong Reaffirms Control Over ImmunityBio with 66.3% Stake - Intellectia AI
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
ImmunityBio Stock Is Up 18% This Week: Here’s What Global ANKTIVA Approvals Mean - TIKR.com
ImmunityBio (NASDAQ:IBRX) Trading Down 17.4% on Insider Selling - MarketBeat
Dr. Patrick Soon-Shiong will participate as a speaker at the "Cancer 2035: A Roadmap for the Future" - Oncodaily
Why ImmunityBio Stock Is Soaring Today - AOL.com
Biotech Stocks To Follow TodayFebruary 25th - MarketBeat
ImmunityBio Supersedes Expectations With Fivefold Revenue IncreaseImmunityBio (NASDAQ:IBRX) - Benzinga
ImmunityBio Stock (IBRX) Opinions on Saudi Launch and EU Approval - Quiver Quantitative
ImmunityBio (NASDAQ:IBRX) Trading Down 8.8% Following Insider Selling - MarketBeat
ImmunityBio Faces Intense Scrutiny as Legal Concerns Mount - timothysykes.com
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate - Finviz
ImmunityBio’s 471% Surge Could Trigger A Massive Short SqueezeImmunityBio (NASDAQ:IBRX) - Benzinga
ImmunityBio Shares Surge on Stellar Revenue Growth and Regulatory Milestones - AD HOC NEWS
ImmunityBio Surges as Anktiva Drives 671% Revenue Growth - Tokenist
ImmunityBio: Disconnect Between Clinical Progress And Stock Performance (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus - TechStock²
Q1 Earnings Estimate for ImmunityBio Issued By HC Wainwright - MarketBeat
ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption - Finviz
ImmunityBio (IBRX) Revenue Ramp To US$38 Million Tests Profitability Optimism - simplywall.st
IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook - Meyka
ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump - Insider Monkey
ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells $250,000.00 in Stock - MarketBeat
ImmunityBio, Inc. (IBRX): Harnessing a 407% Revenue Growth with a Promising 28% Upside Potential - DirectorsTalk Interviews
Selecky of Immunitybio sells $250,000 in shares - Investing.com
Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million - Investing.com
IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move - Stocktwits
Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million By Investing.com - Investing.com Nigeria
Selecky of Immunitybio sells $250,000 in shares By Investing.com - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Trading Up 17.5%Here's Why - MarketBeat
ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN
ImmunityBio's Anktiva Drives Record Revenue Amid Global Expansion Push - AD HOC NEWS
ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity - Yahoo Finance
ImmunityBio (IBRX) Stock Explodes 500%+ in 2026 on ANKTIVA's 700% Revenue Surge - International Business Times Australia
ImmunityBio Expands Reach: ANKTIVA Gains Conditional EU Approval - StocksToTrade
European Nod Boosts ImmunityBio’s Market Presence - timothysykes.com
ImmunityBio (NASDAQ:IBRX) Reaches New 1-Year HighTime to Buy? - MarketBeat
ImmunityBio reports $113M in ANKTIVA sales, up 700% in 2025 By Investing.com - Investing.com India
Goldman Sachs, H.C. Wainwright Maintain Buy on ImmunityBio, Inc. (IBRX) Feb 2026 - Meyka
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
0.68%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):